Literature DB >> 19836494

Secondary and tertiary hyperparathyroidism, state of the art surgical management.

Susan C Pitt1, Rebecca S Sippel, Herbert Chen.   

Abstract

This article reviews the current surgical management of patients with secondary and tertiary hyperparathyroidism. The focus is on innovative surgical strategies that have improved the care of these patients over the past 10 to 15 years. Modalities such as intraoperative parathyroid hormone monitoring and radioguided probe utilization are discussed.

Entities:  

Mesh：

Year:  2009        PMID： 19836494      PMCID： PMC2905047          DOI： 10.1016/j.suc.2009.06.011

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN： 0039-6109            Impact factor:   2.741


  41 in total

1.  The role of intraoperative parathyroid hormone testing in patients with tertiary hyperparathyroidism after renal transplantation.

Authors:  Silke V Haustein; Eberhard Mack; James R Starling; Herbert Chen
Journal:  Surgery       Date:  2005-12       Impact factor: 3.982

2.  Utility of an intraoperative gamma probe in the surgical management of secondary or tertiary hyperparathyroidism.

Authors:  Francisca H Jorna; Pieter L Jager; Clara Lemstra; Theo Wiggers; Coen A Stegeman; John T M Plukker
Journal:  Am J Surg       Date:  2008-04-23       Impact factor: 2.565

3.  RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.

Authors:  E A Slatopolsky; S K Burke; M A Dillon
Journal:  Kidney Int       Date:  1999-01       Impact factor: 10.612

4.  Intraoperative parathyroid hormone measurement in patients with secondary hyperparathyroidism.

Authors:  Fong-Fu Chou; Chiang-Hsuen Lee; Jin-Bor Chen; Kuo-Tai Hsu; Shyr-Ming Sheen-Chen
Journal:  Arch Surg       Date:  2002-03

5.  Near-total parathyroidectomy is beneficial for patients with secondary and tertiary hyperparathyroidism.

Authors:  Mira Milas; Collin J Weber
Journal:  Surgery       Date:  2004-12       Impact factor: 3.982

6.  Calciphylaxis in patients on hemodialysis: a prevalence study.

Authors:  M Angelis; L L Wong; S A Myers; L M Wong
Journal:  Surgery       Date:  1997-12       Impact factor: 3.982

7.  Tertiary hyperparathyroidism: histologic patterns of disease and results of parathyroidectomy.

Authors:  Electron Kebebew; Quan-Yang Duh; Orlo H Clark
Journal:  Arch Surg       Date:  2004-09

8.  Novel parathyroid hormone (1-84) assay as basis for parathyroid hormone monitoring in renal hyperparathyroidism.

Authors:  Klaus Kaczirek; Gerhard Prager; Philipp Riss; Gerald Wunderer; Reza Asari; Christian Scheuba; Christian Bieglmayer; Bruno Niederle
Journal:  Arch Surg       Date:  2006-02

9.  19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.

Authors:  K J Martin; E A González; M Gellens; L L Hamm; H Abboud; J Lindberg
Journal:  J Am Soc Nephrol       Date:  1998-08       Impact factor: 10.121

10.  Comparison of total parathyroidectomy without autotransplantation and without thymectomy versus total parathyroidectomy with autotransplantation and with thymectomy for secondary hyperparathyroidism: TOPAR PILOT-Trial.

Authors:  Katja Schlosser; Johannes A Veit; Stefan Witte; Emilio Domínguez Fernández; Norbert Victor; Hans-Peter Knaebel; Christoph M Seiler; Matthias Rothmund
Journal:  Trials       Date:  2007-09-18       Impact factor: 2.279
View more
  49 in total

1.  Potential treatment of hypoparathyroidism with recombinant plasmids encoding preproparathyroid hormone.

Authors:  D Liu; Y Zhu; C Yang; J Long; C Yao; J Li; S Wang
Journal:  J Endocrinol Invest       Date:  2011-09-27       Impact factor: 4.256

2.  Secondary hyperparathyroidism: Uncommon cause of a leg ulcer.

Authors:  L B van Rijssen; E E A Brenninkmeijer; E J M Nieveen van Dijkum
Journal:  Int J Surg Case Rep       Date:  2011-10-28

3.  Parathyroid Autotransplantation During Thyroid Surgery: A Novel Technique Using a Cell Culture Nutrient Solution.

Authors:  Fausto Famà; Marco Cicciù; Francesca Polito; Antonio Cascio; Maria Gioffré-Florio; Arnaud Piquard; Olivier Saint-Marc; Alessandro Sindoni
Journal:  World J Surg       Date:  2017-02       Impact factor: 3.352

4.  [Parathyroid dysfunction and rheumatic manifestations].

Authors:  D P Frey
Journal:  Z Rheumatol       Date:  2011-11       Impact factor: 1.372

Review 5.  Hyperparathyroidism of Renal Disease.

Authors:  Noah K Yuen; Shubha Ananthakrishnan; Michael J Campbell
Journal:  Perm J       Date:  2016-07-22

Review 6.  The surgical management of renal hyperparathyroidism.

Authors:  Catherine Madorin; Randall P Owen; William D Fraser; Phillip K Pellitteri; Brian Radbill; Alessandra Rinaldo; Raja R Seethala; Ashok R Shaha; Carl E Silver; Matthew Y Suh; Barrie Weinstein; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-11-20       Impact factor: 2.503

7.  Effects of time on ultrastructural integrity of parathyroid tissue before cryopreservation.

Authors:  Carlos Eduardo Santa Ritta Barreira; Cláudio Roberto Cernea; Lenine Garcia Brandão; Melani Ribeiro Custódio; Elia Tamaso Espin Garcia Caldini; Fábio Luiz de Menezes Montenegro
Journal:  World J Surg       Date:  2011-11       Impact factor: 3.352

Review 8.  Surgical management of secondary hyperparathyroidism in chronic kidney disease--a consensus report of the European Society of Endocrine Surgeons.

Authors:  Kerstin Lorenz; Detlef K Bartsch; Juan J Sancho; Sebastien Guigard; Frederic Triponez
Journal:  Langenbecks Arch Surg       Date:  2015-10-02       Impact factor: 3.445

Review 9.  Parathyroid conditions in childhood.

Authors:  Jocelyn F Burke; Herbert Chen; Ankush Gosain
Journal:  Semin Pediatr Surg       Date:  2014-03-15       Impact factor: 2.754

10.  Comparison of hyperparathyroidism types and utility of dual radiopharmaceutical acquisition with Tc99m sestamibi and 123I for localization of rapid washout parathyroid adenomas.

Authors:  Y S Kushchayeva; S H Tella; S V Kushchayev; D Van Nostrand; K Kulkarni
Journal:  Osteoporos Int       Date:  2019-01-31       Impact factor: 4.507
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.